GRTX · As filed with the SEC
Galera Therapeutics income statement, by quarter
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) · USD
| USD | Q1 2026 3 months ended Mar 31, 2026 | Q4 2025† 3 months ended Dec 31, 2025 | Q3 2025 3 months ended Sep 30, 2025 | Q2 2025 3 months ended Jun 30, 2025 | Q1 2025 3 months ended Mar 31, 2025 | Q4 2024† 3 months ended Dec 31, 2024 |
|---|---|---|---|---|---|---|
| Operating expenses: | ||||||
| Research and development | 15,000 | — | 130,000 | 84,000 | 93,000 | — |
| General and administrative | 1,640,000 | — | 1,306,000 | 1,051,000 | 1,870,000 | — |
| Write-off of acquired intangible asset | — | 0† | 0 | — | — | 0† |
| Write-off of goodwill | — | 0† | 0 | — | — | 0† |
| Gain on litigation settlement | — | 0† | 0 | — | — | (1,950,000)† |
| Loss from operations | (1,655,000) | — | (1,436,000) | (1,135,000) | (1,963,000) | — |
| Other income : | ||||||
| Interest income | 49,000 | — | 48,000 | 60,000 | 77,000 | — |
| Change in fair value of warrant liability | 0 | — | 0 | 0 | 294,000 | — |
| Foreign currency loss | — | 0† | 0 | 0 | — | 0† |
| Loss before income tax benefit | — | 153,104,000† | (1,388,000) | — | — | (4,931,000)† |
| Income tax benefit | — | 0† | 0 | — | — | 0† |
| Net loss | (1,606,000) | — | (1,388,000) | (1,075,000) | (1,592,000) | — |
| Net loss attributable to common stockholders, basic | (726,000) | — | (628,000) | (486,000) | (720,000) | — |
| Series B Redeemable Convertible Preferred Stockholders | (880,000) | — | (760,000) | (589,000) | (872,000) | — |
| Net loss attributable to common stockholders, diluted | (726,000) | — | (628,000) | (486,000) | (720,000) | — |
| Series B Redeemable Convertible Preferred Stockholders | (880,000) | — | (760,000) | (589,000) | (872,000) | — |
| Weighted-average shares of common stock outstanding, basic | 98,503,430 | — | 98,503,430 | 98,503,430 | 98,503,430 | — |
| Series B Redeemable Convertible Preferred Stock | 119,318 | — | 119,318 | 119,318 | 119,318 | — |
| Weighted-average shares of common stock outstanding, diluted | 98,503,430 | — | 98,503,430 | 98,503,430 | 98,503,430 | — |
| Series B Redeemable Convertible Preferred Stock | 119,318 | — | 119,318 | 119,318 | 119,318 | — |
| Net loss per share of common stock, basic | (0.01) | — | (0.01) | 0 | (0.01) | — |
| Series B Redeemable Convertible Preferred Stock | (7.37) | — | (6.37) | (4.94) | (7.31) | — |
| Net loss per share of common stock, diluted | (0.01) | — | (0.01) | 0 | (0.01) | — |
| Series B Redeemable Convertible Preferred Stock | (7.37) | — | (6.37) | (4.94) | (7.31) | — |
† Derived: worked out from the filings, not stated in them. A fourth quarter is the 10-K year less the nine months in the third-quarter 10-Q; a quarter of cash flows is year to date less the prior year to date.
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.